Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
During the decade 1987-1996, the Developmental Therapeutics Program (DTP) of the National Cancer Institute (NCI) provided infrastructure support for both intramural and extramural anti-HIV (human immunodeficiency virus) drug discovery research and development. This retrospective review describes some of the anti-HIV lead discovery and development that took place under DTP auspices or which was substantially facilitated by resources made available through the DTP. Examples highlighted include leads identified through the initial screening of pure natural product derived compounds and those derived from bioassay-guided fractionation of crude natural product extracts, and these are classified according to the mechanism of action targeting the critical steps within the replication cycle of HIV.
Yang
S S
SS
Developmental Therapeutics Program, National Cancer Institute, Bethesda, Maryland 20892, USA. stringns@mail.nih.gov
Cragg
G M
GM
Newman
D J
DJ
Bader
J P
JP
D000595:Amino Acid Sequence; D019380:Anti-HIV Agents / Q000302:isolation & purification*; D015497:HIV-1 / Q000502:physiology; D008954:Models, Biological; D008956:Models, Chemical; D008969:Molecular Sequence Data; D009316:National Institutes of Health (U.S.); D012189:Retrospective Studies; D014481:United States; D014779:Virus Replication
D019380:Anti-HIV Agents